Are written proceedings before the UPC truly public? A tale of three access requests
The fates of three requests for access to pleadings and evidence filed with the Unified Patent Court (UPC) demonstrate how the judges of the UPC are still struggling with the court’s commitment to… read more…
UKIPO Launches Standards Essential Patents Resource Hub
As we reported on in 2022, the UKIPO has been working with stakeholders to assist in the challenges faced by industry with respect to standards essential patents (SEPs) This work has resulted in the… read more…
Ever more patent proprietors opting for the Unitary Patent
Since March, the rate at which European patents granted by the European Patent Office (EPO) are converted to Unitary Patents has risen from 18% to 243%, an increase of 35% The figures… read more…
Emotional Perception High Court ruling overturned by Court of Appeal
On 19 July 2024, the Court of Appeal under Lord Justice Birss handed down its judgement on the case of Comptroller – General of Patents, Designs and Trade Marks v Emotional Perception AI Limited… read more…
Referral on fundamental questions of claim interpretation at the EPO (G 1/24)
The EPO Board of Appeal in decision T 0439/22 of 24 June 2024 referred new questions to the Enlarged Board of Appeal on whether and to what extent the description and drawings can be taken into… read more…
Mathys & Squire Partners discuss the importance of protecting IP in the alternative proteins industry
Mathys & Squire Partners Laura Clews and Chris Hamer were recently interviewed by Protein Production Technology International (PPTI) and provided commentary on various issues relating to… read more…
Filings of secret ‘National Security’ patents increase 36% in a year amid military tech developments
Commentary by Partner Andrew White has been featured in Law 360, Solicitors Journal, The Patent Lawyer and The Global Legal Post, discussing how an increase in defence spending is thought to be… read more…
Changes to the proposed new medicinal products Directive have been approved by the EU Parliament – do they shift the balance between generics and innovators and are they TRIPS compliant?
Introduction In April 2023 the EU published draft legislation which, if enacted, would represent a major shift in the regulatory and IP framework for pharmaceutical products in Europe[1] As… read more…
Mathys & Squire files Petition for Review for Ipsen Bioinnovation
Mathys & Squire attorneys: David Hobson, Martin MacLean and Nicholas Fox have filed a Petition for Review on behalf of Ipsen Bioinnovation asking the European Patent Office’s (EPO)… read more…
